Sucampo Pharmaceuticals Inc. (SCMP) Stock Price Up 2.7%
Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) rose 2.7% during mid-day trading on Monday . The company traded as high as $12.83 and last traded at $12.66, with a volume of 203,644 shares trading hands. The stock had previously closed at $12.33.
SCMP has been the topic of a number of research analyst reports. Maxim Group reissued a “buy” rating on shares of Sucampo Pharmaceuticals in a research note on Monday, July 11th. Mizuho reissued a “buy” rating on shares of Sucampo Pharmaceuticals in a research note on Monday, July 11th. Roth Capital restated a “buy” rating on shares of Sucampo Pharmaceuticals in a report on Tuesday, July 12th. Jefferies Group decreased their price objective on Sucampo Pharmaceuticals from $16.00 to $14.00 and set a “hold” rating on the stock in a report on Thursday, August 4th. Finally, Zacks Investment Research upgraded Sucampo Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, August 8th. Five investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $19.20.
The company has a 50-day moving average of $11.73 and a 200-day moving average of $11.38. The company has a market cap of $547.54 million, a price-to-earnings ratio of 44.88 and a beta of 1.28.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/19/sucampo-pharmaceuticals-inc-scmp-stock-price-up-2-7.html
Sucampo Pharmaceuticals (NASDAQ:SCMP) last released its quarterly earnings results on Wednesday, August 3rd. The biopharmaceutical company reported $0.23 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.22 by $0.01. Sucampo Pharmaceuticals had a return on equity of 42.18% and a net margin of 6.65%. The business earned $52 million during the quarter, compared to analysts’ expectations of $48.33 million. During the same quarter in the prior year, the business earned $0.21 earnings per share. The company’s quarterly revenue was up 49.1% compared to the same quarter last year. Equities research analysts expect that Sucampo Pharmaceuticals Inc. will post $1.03 earnings per share for the current year.
Several large investors have recently added to or reduced their stakes in the company. Pacad Investment Ltd. bought a new stake in Sucampo Pharmaceuticals during the first quarter valued at approximately $528,000. Teachers Advisors Inc. boosted its position in Sucampo Pharmaceuticals by 38.5% in the first quarter. Teachers Advisors Inc. now owns 423,391 shares of the biopharmaceutical company’s stock valued at $4,628,000 after buying an additional 117,700 shares during the last quarter. Algert Global LLC boosted its position in Sucampo Pharmaceuticals by 33.9% in the first quarter. Algert Global LLC now owns 19,232 shares of the biopharmaceutical company’s stock valued at $210,000 after buying an additional 4,872 shares during the last quarter. Mckinley Capital Management LLC Delaware boosted its position in Sucampo Pharmaceuticals by 147.7% in the first quarter. Mckinley Capital Management LLC Delaware now owns 232,824 shares of the biopharmaceutical company’s stock valued at $2,545,000 after buying an additional 138,829 shares during the last quarter. Finally, BlackRock Fund Advisors boosted its position in Sucampo Pharmaceuticals by 3.1% in the first quarter. BlackRock Fund Advisors now owns 1,630,036 shares of the biopharmaceutical company’s stock valued at $17,816,000 after buying an additional 48,420 shares during the last quarter. Institutional investors and hedge funds own 40.64% of the company’s stock.
Sucampo Pharmaceuticals Company Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on research and development of drugs to treat gastrointestinal, ophthalmic and oncology-based inflammatory disorders. It operates through development and commercialization of pharmaceutical products segment. Its operations are conducted through Sucampo AG, based in Zug, Switzerland, through which the Company conducts certain worldwide and European operations; Sucampo Pharma, LLC, based in Tokyo and Osaka, Japan and R-Tech Ueno, Ltd., based in Kobe, Japan, through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC, based in Rockville, Maryland, through which the Company conducts operations in North and South America, and Sucampo Pharma Europe, Ltd., based in Oxford, the United Kingdom.
Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.